The bioprocessing industry has undergone a rapid series of ebbs and flows over the past few years. Once riding high on a wave of growth driven by the urgent demands of the COVID-19 pandemic, the industry has recently experienced a marked downturn. The question on everyone’s mind is: Is the recovery
The biopharmaceutical industry has seen significant advancements, particularly in the production of monoclonal antibodies (mAbs), which offer personalized therapies for a range of chronic and debilitating conditions. Despite these advancements, manufacturers face growing pressure to expedite the
The launch of the Planova FG1 by Asahi Kasei Medical marks a pivotal advancement in virus removal technology within the bioprocessing industry. This next-generation virus removal filter is designed to enhance efficiency and safety in the production of biotherapeutics, including biopharmaceuticals
Monoclonal antibodies (mAbs) have become a cornerstone of modern medicine, offering targeted therapies for a range of diseases, including various cancers, autoimmune disorders, and infectious diseases. However, developing these complex molecules is resource-intensive, requiring significant time and
The biopharmaceutical industry has witnessed significant advancements in upstream bioprocessing over the years, but downstream bioprocessing (DSP) often lagged, creating bottlenecks that hampered overall efficiency. Recent innovations, however, are transforming the DSP landscape, offering promising
The biopharmaceutical industry is on the cusp of a revolutionary transformation that promises to redefine its future trajectory. While Biopharma 4.0 brought about significant advancements in digitization and smart manufacturing, its successor, Biopharma 5.0, aims to integrate human creativity,
